We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

BECKMAN COULTER, INC.

Beckman Coulter develops, manufactures and markets laboratory systems, reagents, centrifugation, lab automation, elec... read more Featured Products: More products

Download Mobile App




Collaboration Advances Extracellular Vesicle-Based Tests for Neurodegenerative Diseases

By LabMedica International staff writers
Posted on 23 Jul 2026

NanoSomiX, Inc. More...

and Beckman Coulter Diagnostics announced a collaboration to explore the development of next-generation immunoassays for neurodegenerative diseases using extracellular vesicles (EVs). The effort builds on NanoSomiX’s focus on blood-based analytics using EVs, including those derived from brain tissue. The companies emphasize a shared interest in addressing the challenge of detecting low-abundance, brain-specific biomarkers in blood. NanoSomiX’s proprietary platform targets EVs derived from defined brain cell populations, including neurons and glial cells.

Brain-derived EVs can provide access to clinically meaningful signals from a small volume of blood. NanoSomiX has developed EV-based immunoassays that measure biomarkers isolated from neuron- and other brain cell–derived EVs. These assays are intended to support research into disease mechanisms, progression, and therapeutic response.

NanoSomiX reports that its EV-based immunoassay platforms have been developed, published, and shown to be compatible with high-throughput testing systems. The platform is positioned as a foundation for translational research and scalable immunoassay development. The company is also collaborating with academic and commercial partners on projects involving neuron-, astrocyte-, and oligodendrocyte-derived EVs to advance biomarker discovery and validation across neurological conditions and neuroinjury.

“EVs—particularly brain‑derived EVs—offer a non‑invasive way to access meaningful signals from the brain using a small volume of blood. NanoSomiX has developed EV‑based immunoassays that measure biomarkers from neuron‑ and other brain cell–derived EVs, supporting research into disease mechanisms, progression, and therapeutic response. We are excited to work with Beckman Coulter Diagnostics to help translate this scientific foundation toward scalable, automated immunoassay solutions for both research and clinical settings,” said Dr. Dennis Van Epps, VP, Scientific Affairs, NanoSomiX.


Gold Member
Nucleic Acid Extractor System
NEOS-96 XT
Online QC Software
Acusera 24•7
Prefilled Tubes
Prefilled 5.0ml Tubes
Creatinine/eGFR Meter
StatSensor® Creatinine/eGFR Meter
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: Visual Abstract (Seemesh Bhaskar et al., Point of care molecular cancer diagnostics, Lab on a Chip, 2026. DOI: 10.1039/d5lc01014d)

Point-of-Care Molecular Technology Promises Transformative Shift in Oncology

Delays in obtaining molecular test results can hinder timely oncology decisions and widen disparities for patients far from centralized laboratories. Prolonged waits may also heighten anxiety and increase... Read more

Immunology

view channel
Image: New findings show unique pathogen‑directed antibody patterns are already present years ahead of a formal diagnosis of inflammatory bowel disease (Image Credit: iStock)

Antibody Profiling Identifies Preclinical Inflammatory Bowel Disease Years Before Diagnosis

Inflammatory bowel disease often develops after a prolonged symptom-free period, complicating timely recognition and clinical intervention. Limited understanding of immune activity during this silent phase... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.